PDCD1 and non-small cell lung carcinoma: Other trials (e.g., KEYVIBE–007, AdvanTIG–302) are ongoing to further evaluate 1st–line anti–TIGIT (e.g., vibostolimab, ociperlimab) plus anti–PD–1 therapy for NSCLC.